Active Pharmaceutical Ingredients, APIs, are the essential components of a medicine that provide the therapy needed for the patient. These chemical and biological compounds are formulated and manufactured into finished dosage forms – tablets, solutions, creams – for administration.
The challenge in securing enough API to meet the nation’s needs has been highlighted in the June 2021 White House report of Supply Chain Resiliency2 which referenced the epidemic of national drug shortages before COVID and the pandemic itself.
The focus of this examination is to provide a deeper view into the US manufacturing infrastructure associated with API production.